NCT07708337Not yet recruiting
Evaluating Customized Antibiotic Duration (CDA) Strategy in Acute Exacerbations of COPD
Evaluating Customized Antibiotic Duration (CDA) Strategy in Acute Exacerbations of COPD: Protocol for Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn whether a shorter course of antibiotics (7 days) works as well as the usual longer course (14 days) for adults admitted to hospital with a flare-up of chronic obstructive pulmonary disease (COPD), a long-term lung disease. The trial takes place at CDA Hospital Islamabad, Pakistan. The main questions it aims to answer are: * Do patients who take antibiotics for 7 days recover as well by Day 30 as patients who take them for 14 days? * Does the shorter course lead to fewer side effects and less antibiotic use, without more treatment failures, relapses or hospital readmissions? Researchers will compare a 7-day antibiotic course with the usual 14-day course to see if the shorter course is just as effective. Participants will: * Be assigned by chance (like flipping a coin) to take antibiotics for either 7 days or 14 days. Their doctor chooses which antibiotic to use. * Receive all other usual hospital care for their COPD flare-up. * Have check-ups about 3-5 days, 7 days, 14 days and 30 days after joining the trial, in hospital or by telephone, to record their symptoms, any side effects and any return to hospital. About 560 adults will take part.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 560 (estimated)
- First submitted
- 3 Jul 2026
- Start date
- 26 Oct 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Capital Development Authority (CDA)
- Diseases
- COPD
- NCT number
- NCT07708337
What you commit to
- Study type: Interventional
- Planned participants: 560
- From 26 Oct 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous enrolment in this trial, or current participation in another interventional trial in AECOPD.
Other illness
- A documented infection that requires a defined, longer antibiotic course, such as pneumonia with complications, an exacerbation of bronchiectasis, lung abscess or empyema.
- Severe immunosuppression, for example neutropenia, active malignancy under chemotherapy, organ transplantation or advanced HIV infection.
- Suspected or confirmed pulmonary tuberculosis, or another respiratory infection that needs a different antimicrobial approach.
Other
- Need for immediate admission to intensive care or for invasive mechanical ventilation at presentation.
- Pregnancy or breastfeeding.
- Systemic antibiotic treatment for the current exacerbation started more than 48 hours before randomisation.
Who the study is looking for
- Adults aged 18 years or older.
- Physician-diagnosed COPD, confirmed by post-bronchodilator spirometry (FEV1/FVC \< 0.70) where available, or by documented previous spirometry consistent with COPD.
- A current acute exacerbation of COPD for which the treating physician judges antibiotic therapy to be necessary, with at least two of the three cardinal symptoms (increased dyspnoea, increased sputum volume, increased sputum purulence).
- Able and willing to give written informed consent and to follow the study procedures and follow-up schedule.
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CDA Hospital Islamabad Coordinator of this site? Confirm its status | Islamabad | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.